Price T Rowe Associates Inc Eq Rx, Inc. Transaction History

Price T Rowe Associates Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.66 - $2.31 $68,357 - $95,123	-41,179 Reduced 27.55%	108,286 $241,000
Q2 2023 Aug 14, 2023	BUY	$1.61 - $1.96 $42,479 - $51,714	26,385 Added 21.44%	149,465 $279,000
Q1 2023 May 15, 2023	SELL	$1.8 - $2.83 $2.26 Million - $3.55 Million	-1,254,530 Reduced 91.07%	123,080 $239,000
Q4 2022 Feb 14, 2023	SELL	$2.05 - $5.5 $206,496 - $554,015	-100,730 Reduced 6.81%	1,377,610 $3.39 Million
Q3 2022 Nov 14, 2022	BUY	$0.94 - $5.99 $45,670 - $291,030	48,586 Added 3.4%	1,478,340 $7.32 Million
Q2 2022 Aug 15, 2022	SELL	$3.2 - $5.69 $532,380 - $946,639	-166,369 Reduced 10.42%	1,429,754 $6.71 Million
Q1 2022 May 16, 2022	SELL	$2.8 - $7.39 $2.73 Million - $7.22 Million	-976,450 Reduced 37.96%	1,596,123 $6.59 Million
Q4 2021 Feb 14, 2022	BUY	$5.92 - $9.98 $15.2 Million - $25.7 Million	2,572,573 New	2,572,573 $17.5 Million

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.